Corcept Therapeutics (CORT) Earnings Analysis
Corcept Therapeutics (CORT) next reports earnings on 2026-07-30, consensus EPS 0.01227 USD. Last quarter (2026-04-30) it missed with EPS -0.3 USD vs -0.11019 USD est (-172.3%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E 201.96.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CORT next report earnings?
| Next earnings date | 2026-07-30 |
|---|---|
| Consensus EPS estimate | 0.01227 USD |
| Revenue estimate | 0.22B |
CORT earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | -0.3 USD | -0.11019 USD | -172.3% | Miss |
| 2025-07-31 | 0.29 USD | 0.23 USD | +26.1% | Beat |
| 2025-05-05 | 0.17 USD | 0.17 USD | 0% | Beat |
| 2025-02-26 | 0.26 USD | 0.37 USD | -29.7% | Miss |
| 2024-10-30 | 0.41 USD | 0.28 USD | +46.4% | Beat |
| 2024-07-29 | 0.32 USD | 0.23 USD | +39.1% | Beat |
Beat rate: 4/6 (67%) over reported quarters with consensus data.
CORT valuation and analyst view
| Trailing P/E | 201.96 |
|---|---|
| Trailing EPS | 0.45869 USD |
| Price / book | 14.88 |
| Dividend yield | 0.00% |
| Market cap | 10.01B |
| Analyst consensus | Buy (14 buy / 10 hold / 2 sell) |
| Avg price target | 93 USD |
Related research pages
Frequently asked questions
When is Corcept Therapeutics (CORT)'s next earnings date?
Corcept Therapeutics is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 0.01227 USD and revenue estimate of 0.22B.
Did CORT beat earnings last quarter?
In its 2026-04-30 report, CORT posted EPS of -0.3 USD versus a -0.11019 USD estimate — a miss of 172.3%.
What is CORT's earnings track record?
Over the last 6 reported quarters with consensus data, CORT beat estimates 4 times (67%).
What is CORT's current P/E ratio and EPS?
CORT trades at a trailing P/E of 201.96 on trailing EPS of 0.4586872217168574 USD.
What do analysts rate CORT?
Analyst consensus is "Buy" across 26 ratings (0 strong buy, 14 buy, 10 hold, 2 sell, 0 strong sell). Average 12-month price target: 93 USD.